0
1
0
0
1
0
The Neonatal Abstinence Score (NAS), commonly known as the Finnegan Scoring System, is the most widely used clinical tool for assessing and managing withdrawal symptoms in newborns exposed to opioids and other substances in utero. Developed by Dr. Loretta Finnegan in 1975, this standardized scoring system evaluates 21 clinical signs across central nervous system, metabolic, vasomotor, respiratory, and gastrointestinal domains.
Neonatal Abstinence Syndrome affects an estimated 7 per 1,000 hospital births in the United States, a number that increased five-fold between 2004 and 2014 due to the opioid epidemic. NAS occurs when a newborn who was chronically exposed to substances in utero — most commonly opioids (heroin, methadone, buprenorphine, prescription opioids), but also benzodiazepines, SSRIs, or nicotine — experiences withdrawal after delivery when the placental supply is cut off.
Symptoms of NAS typically appear within 24-72 hours of birth for short-acting opioids and 48-144 hours for long-acting opioids like methadone. Clinical features include high-pitched crying, tremors, irritability, poor feeding, sneezing, yawning, sweating, diarrhea, and in severe cases, seizures. The Finnegan score quantifies these symptoms on a scale from 0 to a theoretical maximum of approximately 45.
The score guides treatment decisions: scores ≥ 8 on two consecutive assessments typically indicate the need for pharmacologic intervention, most commonly with morphine or methadone. Scoring is performed every 3-4 hours by trained nursing staff, and treatment is titrated based on score trends. Non-pharmacologic interventions — including swaddling, low-stimulation environments, frequent small feeds, and skin-to-skin contact — are first-line for all infants and often sufficient for those with mild withdrawal.
This calculator implements the full Modified Finnegan Scoring System as recommended by the AAP Committee on Fetus and Newborn and endorsed by the Substance Abuse and Mental Health Services Administration (SAMHSA). While newer tools like the Eat, Sleep, Console (ESC) approach are gaining traction, the Finnegan score remains the most validated and widely used assessment worldwide.
The total score is the sum of all 17 component scores:
CNS Signs: High-pitched cry (0-3), Sleep (0-3), Moro reflex (0-3), Tremors (0-4), Muscle tone (0-2), Excoriation (0-1), Myoclonic jerks (0-3), Seizures (0-5)
Metabolic/Vasomotor: Sweating (0-1), Fever (0-2), Yawning (0-1)
Respiratory: Nasal stuffiness (0-1), Sneezing (0-1), Nasal flaring (0-2), Respiratory rate (0-2)
GI: Feeding (0-3), Stools (0-3)
Severity: 1 = Mild (score 0-7), 2 = Moderate (score 8-11), 3 = Severe (score ≥12). Pharmacologic treatment is indicated when score ≥ 8 on two consecutive assessments.
Score 0-7 (Mild, Severity 1): Non-pharmacologic care is usually sufficient. Continue supportive measures: swaddling, quiet room, demand feeding, skin-to-skin contact. Monitor with repeat scoring every 3-4 hours. Score 8-11 (Moderate, Severity 2): Consider initiating pharmacologic therapy if scores remain ≥8 on 2+ consecutive assessments. Typically start morphine at 0.04-0.08 mg/kg/dose every 3-4 hours. Score ≥12 (Severe, Severity 3): Pharmacologic treatment strongly indicated. May need higher morphine doses or addition of adjunctive agents (phenobarbital, clonidine). Close monitoring for respiratory depression and feeding difficulties.
Inputs
Results
A score of 10 indicates moderate withdrawal. Pharmacologic treatment with morphine should be considered if sustained across 2 assessments.
Inputs
Results
A score of 5 indicates mild withdrawal. Non-pharmacologic supportive care is appropriate. Continue monitoring.
NAS is a group of withdrawal symptoms that occur in newborns exposed to addictive substances (primarily opioids) in utero. When the placental drug supply stops at birth, the infant experiences withdrawal — similar to adult withdrawal but potentially more dangerous due to neonatal vulnerability.
The Finnegan score is assessed every 3-4 hours by trained nurses. Each of 17 signs is scored and summed. Two consecutive scores of 8 or higher typically trigger pharmacologic treatment. Scores guide dose titration — increasing medication for rising scores and weaning for declining scores.
First-line treatment is usually morphine sulfate (0.04-0.08 mg/kg/dose every 3-4 hours) or methadone. Adjunctive agents include phenobarbital (for seizures or polydrug withdrawal) and clonidine (for autonomic symptoms). Treatment is weaned gradually as symptoms improve.
NAS duration varies widely. Short-acting opioid withdrawal typically resolves in 1-3 weeks. Methadone withdrawal may last 4-6 weeks or longer. Some infants require weeks to months of pharmacologic treatment. Non-pharmacologic symptoms can persist for several months.
Non-pharmacologic interventions are first-line for all infants: swaddling, low-light quiet environment, minimal handling, small frequent feedings, pacifier for non-nutritive sucking, skin-to-skin (kangaroo care), rocking/gentle motion, and rooming-in with the mother when appropriate.
Yes, breastfeeding is encouraged for mothers on stable methadone or buprenorphine maintenance (unless other contraindications exist). Small amounts of opioid in breast milk can ease withdrawal symptoms, and the bonding benefits are significant. It has been shown to reduce NAS severity and hospital stay.
ESC is a newer, function-based assessment alternative to Finnegan scoring. It asks: Can the infant eat adequately? Sleep at least 1 hour undisturbed? Be consoled within 10 minutes? ESC focuses on functional capacity rather than individual signs and has shown promising results in reducing pharmacologic treatment and hospital stays.
Opioids are the primary cause: heroin, methadone, buprenorphine, oxycodone, hydrocodone, fentanyl. Other substances include benzodiazepines, barbiturates, SSRIs/SNRIs (causing a separate syndrome), alcohol, and nicotine. Polysubstance exposure often causes more severe withdrawal.
Hospital stays vary from days to months. Infants managed with non-pharmacologic care alone may go home in 4-7 days. Those requiring pharmacologic treatment typically stay 2-6 weeks or longer, depending on weaning duration. The average hospital stay for NAS is approximately 17 days.
NAS can be reduced by treating maternal opioid use disorder with medication-assisted therapy (methadone or buprenorphine), which, while it does not eliminate NAS, typically results in milder withdrawal than illicit opioid use. Comprehensive prenatal care, addiction counseling, and avoiding polydrug use help minimize severity.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!
